Clinical Trials in Sydney, New South Wales
318 recruiting
Showing 1–20 of 226 trials
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Atherosclerotic Cardiovascular Disease
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled240 locationsNCT06459180
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled54 locationsNCT05948943
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Obesity With DiabetesOverweight With Diabetes
Kailera1,700 enrolled37 locationsNCT07284901
Recruiting
Phase 2
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Novartis Pharmaceuticals104 enrolled30 locationsNCT06997588
Recruiting
Phase 3
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
ObesityOverweight
Kailera1,800 enrolled33 locationsNCT07284875
Recruiting
Phase 2
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
Macular Edema
Kiora Pharmaceuticals, Inc.28 enrolled4 locationsNCT06825702
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled164 locationsNCT06824467
Recruiting
Phase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
Non-segmental Vitiligo
Novartis Pharmaceuticals210 enrolled15 locationsNCT07431177
Recruiting
Phase 2
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
Retinitis Pigmentosa
Kiora Pharmaceuticals, Inc.36 enrolled5 locationsNCT06628947
Recruiting
Phase 3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Hyperlipidemia
Merck Sharp & Dohme LLC975 enrolled89 locationsNCT07216482
Recruiting
Not Applicable
Post Market Clinical Follow up of ResMed Mask Systems
Obstructive Sleep Apnea
ResMed500 enrolled1 locationNCT05262439
Recruiting
Phase 3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled103 locationsNCT07227402
Recruiting
Not Applicable
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
Breast CancerRadiotherapy Side EffectSentinel Lymph Node+2 more
Hospital Universitari de Bellvitge820 enrolled60 locationsNCT04889924
Recruiting
Not Applicable
Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1
Prostate Cancer (Adenocarcinoma)
St Vincent's Hospital, Sydney24 enrolled1 locationNCT07552922
Recruiting
Phase 2
Bipolar Androgen Therapy + Carboplatin in mCRPC
Homologous Recombination DeficiencyCastration-resistant Prostate Cancer
St Vincent's Hospital, Sydney30 enrolled1 locationNCT03522064
Recruiting
Phase 1
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
Uveal Melanoma, Metastatic
St Vincent's Hospital, Sydney8 enrolled2 locationsNCT07203391
Recruiting
Phase 1Phase 2
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Gastrointestinal Cancer
Merck Sharp & Dohme LLC180 enrolled62 locationsNCT06596694
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Immunovant Sciences GmbH210 enrolled120 locationsNCT07018323